Skip to main content
. 2022 May 18;12(6):1383–1396. doi: 10.1007/s13555-022-00738-6

Table 3.

Assessment of patient-reported outcomes at baseline

Analysis set
N = 1500
Patients, n (%) 1500 (100.0)
 POEM score, median (min, max) 10.0 (3.0, 28.0)
 POEM severity classification, n (%)
  Mild 517 (34.5)
  Moderate 656 (43.7)
  Severe 246 (16.4)
  Very severe 81 (5.4)
 PP-NRS score, median (min, max) 4.0 (0.0, 10.0)
 PP-NRS severity classification, n (%)
  No itch 24 (1.6)
  Mild itch 696 (46.4)
  Moderate itch 487 (32.5)
  Severe itch 251 (16.7)
  Very severe itch 42 (2.8)
Treatment satisfaction
 PGIC classification, n (%)
  Very much improved 94 (6.3)
  Much improved 460 (30.7)
  Minimally improved 630 (42.0)
  No change 280 (18.7)
  Minimally worse 22 (1.5)
  Much worse 10 (0.7)
  Very much worse 4 (0.3)
 PGIT classification, n (%)
  Extremely satisfied 22 (1.5)
  Very satisfied 114 (7.6)
  Slightly satisfied 341 (22.7)
  Neither dissatisfied nor satisfied 502 (33.5)
  Slightly dissatisfied 389 (25.9)
  Very dissatisfied 107 (7.1)
  Extremely dissatisfied 25 (1.7)
TSQM, mean (SD)
  Effectiveness 51.1 (15.4)
  Convenience 58.3 (15.7)
  Global satisfaction 53.1 (15.8)
Medication adherence
 MMAS-8 score, median (min, max) 3.5 (0.0, 8.0)
 MMAS-8 classification, n (%) 1500 (100.0)
  Low adherence 1249 (83.3)
  Medium adherence 212 (14.1)
  High adherence 39 (2.6)
Atopic dermatitis control
 ADCT score, median (min, max) 7.0 (0.0, 24.0)
 ADCT classification, n (%) 1500 (100.0)
  Good control 396 (26.4)
  Poor control 1104 (73.6)

No. of patients (%) is shown, unless otherwise specified

ADCT Atopic Dermatitis Control Tool, MMAS-8 Morisky Medication Adherence Scale-8, PP-NRS Peak Pruritus Numerical Rating Scale, PGIC Patient’s Global Impression of Change, PGIT Patient’s Global Impression of Treatment, POEM Patient Oriented Eczema Measure, TSQM Treatment Satisfaction with Current Medication